The signal
Start with the strangest one. Over two weeks in July, trademark applications landed at the USPTO for seven pharmaceutical names nobody has ever heard of — YUZEVNI (July 8), then BRAKLAYMA, SOHENJI, IPGUAZU, ZAYLAWAI, ZAYLAWEI in a single batch on July 15, and NEXVOUND on July 20 — each covering "pharmaceutical preparations" for a sweeping list of conditions. Invented names like these are how drug companies reserve branding for products they haven't announced, often years ahead of launch. Intent-to-use filings are one of the few places tomorrow's product plans surface in today's public record. The applicant on all seven: Eli Lilly and Company.
Earlier in the year, three members of the House disclosed purchases of Lilly stock under the STOCK Act — David J. Taylor on February 26, Byron Donalds on April 2, Gilbert Cisneros on April 14. Three members accumulating the same name over seven weeks is what our engine flags as a congressional buy cluster.
And behind both: 28 active Phase 3 trials with Lilly as sponsor and readout dates on the calendar — the nearest expected this August and September (retatrutide in type 2 diabetes, lebrikizumab in allergic rhinitis), with the obesity pipeline (orforglipron, retatrutide-versus-tirzepatide head-to-heads) stacked through 2027.
Three independent signal types — congressional buying, trademark activity, clinical catalysts — leaning the same way across the first half of 2026. LLY currently scores 24/100 on our Convergence Board, direction: bullish.
What we deliberately ignored
On July 23, Lilly Endowment, Inc. filed a Schedule 13G/A disclosing a 9.6% stake. Sounds dramatic; scores zero. It's an amendment to a position the Endowment has held for generations — the definition of routine. Our scoring excludes 13G amendments because "a legacy holder still owns what it owned" is not a signal. We show it on the timeline for completeness and count it for nothing.
The honest version
None of this is a price call on a pharma giant every analyst on Earth already covers. Congress members buy megacaps constantly; trademarks can sit unused forever; Phase 3 readouts cut both ways — several of these 28 will disappoint. A 24/100 reflects exactly that: real, multi-source, directionally-aligned activity at context weight, not conviction weight. Our heavy signals — discretionary insider buy clusters, original activist 13Ds — aren't present here.
What the score does tell you: the public record around Lilly got unusually busy, in one direction, from three unrelated corners of the government's filing systems. Every event links to its primary source — USPTO, the House disclosure PDFs, clinicaltrials.gov. Read them yourself.